This study aimed to characterize the dynamic response of prostate tumors to enzalutamide, a current generation AR antagonist, and to demonstrate the functional significance of IL8 and VEGF signaling in modulating the adaptive tumor response. The gene discussed is CXCL8; the disease is prostate neoplasm.